Sulfasalazine inhibits esophageal cancer cell proliferation by mediating ferroptosis
Chemical Biology & Drug Design · 2023-10 · 102 (4) · 730-737
DOI: 10.1111/cbdd.14281 ↗At a glance
Journal article in Chemical Biology & Drug Design, published online on 2023-06-08. Written by Lai-Bo Yin and 9 co-authors. Institution: Department of Cardiothoracic Surgery, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China. Major MEDLINE topics: Ferroptosis, Esophageal Neoplasms. Cited 27 times so far (Crossref); 33 references.
Abstract (original language)
This study aimed to explore the potential mechanism by which sulfasalazine (SAS) inhibits esophageal cancer cell proliferation. A cell counting kit‐8 (CCK‐8) assay was used to detect the effect of SAS (0, 1, 2, and 4 mM) on the proliferation of TE‐1 cells. Subsequently, TE‐1 cells were divided into control group, SAS group, SAS + ferrostatin‐1 (ferroptosis inhibitor) group, and SAS + Z‐VAD (OH)‐FMK (apoptosis inhibitor) group, and cell proliferation was measured using a CCK‐8 assay. Real‐time quantitative polymerase chain reaction and western blotting were used to determine the expression of solute carrier family member 7 11 (SLC7A11, also called xCT), glutathione peroxidase 4 (GPX4), and acyl‐CoA synthase long‐chain family member 4 (ACSL4) in TE‐1 cells. Measurement of ferroptosis in TE‐1 cells was achieved by flow cytometry. Compared with the control group (0 mM SAS), the proliferation of TE‐1 cells was significantly inhibited by different concentrations of SAS for different time lengths, and 4 mM SAS treatment for 48 h could obtain the maximum inhibition rate (53.9%). In addition, SAS treatment caused a significant decrease in the mRNA and protein expression of xCT and GPX4, and a significant increase in ACSL4 expression in TE‐1 cells treated with SAS. Flow cytometry results showed that the ferroptosis level was significantly increased after SAS treatment. However, the activation of ferroptosis by SAS was partially eliminated by treatment with ferrostatin‐1 or Z‐VAD (OH)‐FMK. In conclusion, SAS inhibits the proliferation of esophageal carcinoma cells by activating the ferroptosis pathway.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiothoracic Surgery, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China.
- The Second Department of Traditional Chinese Medicine, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China.
- Department of Pathology, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China.
Cite
APA
Yin, L. B., Li, Z. W., Wang, J. L., Wang, L., Hou, L., Hu, S. Y., Chen, H., Luo, P., Cui, X. B., & Zhu, J. L. (2023). Sulfasalazine inhibits esophageal cancer cell proliferation by mediating ferroptosis. Chemical Biology & Drug Design, 102(4), 730-737. https://doi.org/10.1111/cbdd.14281
Vancouver
Yin LB, Li ZW, Wang JL, Wang L, Hou L, Hu SY, et al. Sulfasalazine inhibits esophageal cancer cell proliferation by mediating ferroptosis. Chemical Biology & Drug Design. 2023;102(4):730-737. doi:10.1111/cbdd.14281
BibTeX
@article{Yin2023,
author = {Yin, Lai-Bo and Li, Zhi-Wei and Wang, Jing-Ling and Wang, Lei and Hou, Liang and Hu, Si-Yuan and Chen, Huan and Luo, Pan and Cui, Xiao-Bin and Zhu, Jia-Long},
title = {Sulfasalazine inhibits esophageal cancer cell proliferation by mediating ferroptosis},
journal = {Chemical Biology & Drug Design},
year = {2023},
volume = {102},
number = {4},
pages = {730--737},
doi = {10.1111/cbdd.14281}
}
EUVIMED